MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/1352458519885489

Медицинская библиотека · Multiple sclerosis (Houndmills, Basingstoke, England) · 2019

Serum FAM19A5 in neuromyelitis optica spectrum disorders: Can it be a new biomarker representing clinical status?

Lee Hye Lim, Seok Hung Youl, Ryu Han-Wook, Cho Eun Bee, Kim Bong Chul, Kim Byoung Joon, Min Ju-Hong, Seok Jin Myoung, Shin Ha Young, Kang Sa-Yoon, Kwon Oh-Hyun, Lee Sang-Soo, Oh Jeeyoung, Sohn Eun-Hee, Huh So-Young, Cho Joong-Yang, Seong Jae Young, Kim Byung-Jo

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Neuromyelitis optica spectrum disorder (NMOSD) targets astrocytes and elevates the levels of astrocyte-injury markers during attacks. FAM19A5, involved in reactive gliosis, is secreted by reactive astrocytes following central nervous system (CNS) damage.

OBJECTIVE

To investigate the significance of serum FAM19A5 in patients with NMOSD.

METHODS

We collected clinical data and sera of 199 patients from 11 hospitals over 21 months. FAM19A5 levels were compared among three groups: NMOSD with positive anti-aquaporin-4 antibody (NMOSD-AQP4), other CNS demyelinating disease, and healthy controls.

RESULTS

The median serum FAM19A5 level was higher in the NMOSD-AQP4 (4.90 ng/mL (3.95, 5.79)) than in the other CNS demyelinating (2.35 ng/mL (1.83, 4.07), p < 0.001) or healthy control (1.02 ng/mL (0.92, 1.14), p < 0.001) groups. There were significant differences in the median serum FAM19A5 levels between the attack and remission periods (5.89 ng/mL (5.18, 6.98); 4.40 ng/mL (2.72, 5.13), p < 0.001) in the NMOSD-AQP4 group. Sampling during an attack (p < 0.001) and number of past attacks (p = 0.010) were independently associated with increased serum FAM19A5.

CONCLUSION

Serum FAM19A5 was higher in patients with NMOSD-AQP4 and correlated with clinical characteristics. Thus, serum FAM19A5 may be a novel clinical biomarker for NMOSD-AQP4.

Для цитирования: Lee Hye Lim, Seok Hung Youl, Ryu Han-Wook, Cho Eun Bee, Kim Bong Chul, Kim Byoung Joon, Min Ju-Hong, Seok Jin Myoung, Shin Ha Young, Kang Sa-Yoon, Kwon Oh-Hyun, Lee Sang-Soo, Oh Jeeyoung, Sohn Eun-Hee, Huh So-Young, Cho Joong-Yang, Seong Jae Young, Kim Byung-Jo. Serum FAM19A5 in neuromyelitis optica spectrum disorders: Can it be a new biomarker representing clinical status?. Multiple sclerosis (Houndmills, Basingstoke, England). 2019. DOI: 10.1177/1352458519885489.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.